Although amylin was discovered decades ago, its importance in everyday clinical practice has long been underestimated. New pharmacological developments are increasingly bringing amylin into the focus of diabetes and obesity therapy, and amylin analogs, some of which have already passed phase 3 clinical trials, are now among the most promising approaches in overweight and obesity pharmacotherapy.
Autoren
- Dr. Stephanie Niklaus
- Prof. Dr. med. vet. Thomas A. Lutz
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Acute nonspecific back pain
Implementing a biopsychosocial approach
- Psychedelic-assisted therapy
Current status of PAT
- Neuropathic Pain
Evidence-Based Neuromodulation Based on Clinical Trials and Real-World Data
- Fibromyalgia Syndrome
Development, Diagnosis, Epidemiology, and Treatment of a Disease Entity
- Juvenile Idiopathic Arthritis
Early Detection and Targeted Treatment in an Interdisciplinary Setting
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib
First-class immunomodulation combined with convenience—the data available so far is convincing
- Chronic hand eczema: common, long-lasting, and distressing
Non-steroidal anti-inflammatory treatment options are essential for long-term management
- Disorders of the Gut-Brain Interaction